Tarlatamab-dlle
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager.
Journal: Immunotherapy
Published: May 04, 2026
Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors.
Journal: Gynecologic oncology
Published: December 01, 2025
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 28, 2025
Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 23, 2025
The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways.
Journal: Therapeutic innovation & regulatory science
Published: February 21, 2025
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer.
Journal: Current treatment options in oncology
Published: September 25, 2024
Tarlatamab (Imdelltra) for small cell lung cancer.
Journal: The Medical letter on drugs and therapeutics
Published: July 09, 2024
Showing 1-10 of 10
Last Updated: 06/30/2026